Jay Jayalath

Final long-term outcomes of a phase II trial + expanded cohort (N=126) of NAC for high-risk localized UTUC. 15-20% complete response (ypT0 N0) and 60-70% overall response (<ypT2 N0) rates. Responders achieved 90% CSS at 7 years. @EUplatinum @UrologyMSK doi.org/10.1016/j.euru…

As we head into #EAU26, I'm thrilled to see that PROGRxN-BCa is now included in the newest EAU NMIBC guidelines! Grateful to @paolo_gontero and the entire guidelines panel for including our work! 📄: doi.org/10.1016/j.euru… @UofTUrology @UofTSurgery @UofT_TCAIREM @CanUrolAssoc

New data on outcomes after consolidative nephrectomy published in EU Oncology! Our findings suggest that a major pathologic response after ICI therapy for metastatic RCC is associated with long PFS and OS. Full study here: sciencedirect.com/science/articl…

🎉 The @AmerUrological and the UCF are excited to recognize 12 researchers as recipients of the 2025 Urology Care Foundation Research Scholar Awards! This program has invested over $30 million to support over 675 Research Scholars! Click to learn more 👉 bit.ly/48G1Iyn

Hot off the press. With 1 in 3 patients harbouring residual viable disease in the testis, radical orchiectomy remains necessary in patients who receive upfront chemotherapy for metastatic testicular cancer. doi.org/10.1016/j.euro… @RichMatulewicz @UrologyMSK

No treatment option in testis cancer is risk-free. The better informed we are, the better we can guide patients through their journey. Nice work @moosemousa @RHamiltonUrol @DavidDan_Ngn @UofTUrology! @JNCI_Now @TestesCancer

Prospective data on short term postoperative recovery after radical orchiectomy. We hope this can be used to counsel and set patient expectations. "Recovery Tracker" is one of many patient reported outcome / HRQoL initiatives in GCT on going at @UrologyMSK @TestesCancer

🚨Updated data on post-chemo RPLND for NSGCT from @UrologyMSK 📜@Annals_Oncology 👏@RichMatulewicz 👇Many great summary figures 🔗shorturl.at/090M7

Updated Long-Term Follow-up from a Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients with High-Grade #UTUC. Presentation by @vhjayalath @MSKCancerCenter. #GU25 written coverage by @RKSayyid @USC > bit.ly/41hrOG8 @ASCO

@WallisCJD “You either die a hero, or live long enough to see yourself become the villain” - Harvey Dent, The Dark Knight

Great work @justin_jin_kim and Mike Chua! Making @UofTUrology proud!!

@MichaelPiasecz1 When was the last time you saw an animal wash their hands?

@Bondzi23 @UofTUpsurge @UofT @uoftmedicine @BlackHealthCAN @blackdocscanada @thebpao @bmsacanada @kwadwo777 @NaheedD @TorontoStar Love to see it

Had the pleasure throughout July to spend time with the young surgeons of the Future ❗️👩🏾‍⚕️👨🏾‍⚕️ To see it, is to believe it. A diverse work force improves patient outcomes and quality care. @UofTUpsurge #MedTwitter #ILookLikeASurgeon #ILookLikeADoctor 📸 IG: @lauraproctorphoto

11.3% of PCa patients with biochemical failure have MLN metastasis on18F-DCFPyL-PET/CT. pT3b disease is associated with 4.31-fold significantly increased odds of MLN metastasis. ⁦@RKSayyid⁩ leading this work💪 bjui-journals.onlinelibrary.wiley.com/doi/abs/10.111…

@moosemousa @UofTUrology @UroOnc @SUO_YUO 🐐

Thrilled to have matched to the Toronto SUO Oncology fellowship! The opportunity to continue learning from invaluable mentors in a city that I love, alongside people that I love is a blessing @UofTUrology @UroOnc @SUO_YUO

Thrilled to be following in the footsteps of so many before me, and continue to learn from the best. Looking forward to the next chapter! Thanks to everyone who helped get me here.

⭐️ 🦌⭐️

@MDTPelvicHealth @DrDeanElterman @UHN Congrats @DrDeanElterman !!

Congratulations @DrDeanElterman of University Health Network, @UHN on earning recognition as an InterStim™ Center of Excellence, the first to be located outside of the United States. We are proud to partner with you to bring InterStim™ systems to patients in Canada.

@DrDeanElterman 2 uro-oncologists who are 2.5 years out from entering practice @DrDeanElterman @moosemousa @UroOncMD

Looking for suggestions #urotwitter Your hospital is designing a new surgical tower with new ORs. They ask “what does urology want”? Big items like what kind of bed, fluoro, lights, cameras etc. For all users (Endo, Onc, Functional) What’s on your 1) must have 2) dream list?

Excited to share that our study assessing the utility of LDH in CSI testicular cancer surveillance is published in @JUrology! Grateful to @RHamiltonUrol for the opportunity and mentorship. @UofTUrology